560 related articles for article (PubMed ID: 8706040)
21. The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer, and its relevance as an autocrine growth factor.
Chatzaki E; Bax CM; Eidne KA; Anderson L; Grudzinskas JG; Gallagher CJ
Cancer Res; 1996 May; 56(9):2059-65. PubMed ID: 8616851
[TBL] [Abstract][Full Text] [Related]
22. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
Günthert AR; Gründker C; Bongertz T; Schlott T; Nagy A; Schally AV; Emons G
Am J Obstet Gynecol; 2004 Oct; 191(4):1164-72. PubMed ID: 15507937
[TBL] [Abstract][Full Text] [Related]
23. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
[TBL] [Abstract][Full Text] [Related]
24. Peptidomimetic GnRH antagonist AEZS-115 inhibits the growth of ovarian and endometrial cancer cells.
Engel JB; Hahne JC; Häusler SF; Meyer S; Segerer SE; Diessner J; Dietl J; Honig A
Anticancer Res; 2012 May; 32(5):2063-8. PubMed ID: 22593489
[TBL] [Abstract][Full Text] [Related]
25. Antitumour effect of a gonadotropin-releasing-hormone antagonist (MI-1544) and its conjugate on human breast cancer cells and their xenografts.
Vincze B; Pályi I; Daubner D; Kálnay A; Mezö G; Hudecz F; Szekerke M; Teplán I; Mezö I
J Cancer Res Clin Oncol; 1994; 120(10):578-84. PubMed ID: 7929528
[TBL] [Abstract][Full Text] [Related]
26. Involvement of annexin V in antiproliferative effects of gonadotropin-releasing hormone agonists on human endometrial cancer cell line.
Shibata S; Sato H; Ota H; Karube A; Takahashi O; Tanaka T
Gynecol Oncol; 1997 Aug; 66(2):217-21. PubMed ID: 9264565
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of a stable gonadotropin-releasing hormone analog in mice for the treatment of endocrine disorders and prostate cancer.
Katsila T; Balafas E; Liapakis G; Limonta P; Montagnani Marelli M; Gkountelias K; Tselios T; Kostomitsopoulos N; Matsoukas J; Tamvakopoulos C
J Pharmacol Exp Ther; 2011 Mar; 336(3):613-23. PubMed ID: 21106905
[TBL] [Abstract][Full Text] [Related]
28. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines.
Emons G; Schröder B; Ortmann O; Westphalen S; Schulz KD; Schally AV
J Clin Endocrinol Metab; 1993 Dec; 77(6):1458-64. PubMed ID: 8263128
[TBL] [Abstract][Full Text] [Related]
29. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
30. Is lGnRH-III the most potent GnRH analog containing only natural amino acids that specifically inhibits the growth of human breast cancer cells?
Herédi-Szabó K; Murphy RF; Lovas S
J Pept Sci; 2006 Nov; 12(11):714-20. PubMed ID: 16967433
[TBL] [Abstract][Full Text] [Related]
31. Growth inhibition of tumor cells in vitro by using monoclonal antibodies against gonadotropin-releasing hormone receptor.
Lee G; Ge B
Cancer Immunol Immunother; 2010 Jul; 59(7):1011-9. PubMed ID: 20182875
[TBL] [Abstract][Full Text] [Related]
32. Proliferation of TSU-Pr1, a human prostatic carcinoma cell line is stimulated by gonadotropin-releasing hormone.
Enomoto M; Seong JY; Kawashima S; Park MK
Life Sci; 2004 May; 74(25):3141-52. PubMed ID: 15081579
[TBL] [Abstract][Full Text] [Related]
33. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
[TBL] [Abstract][Full Text] [Related]
34. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling.
Wells A; Souto JC; Solava J; Kassis J; Bailey KJ; Turner T
Clin Cancer Res; 2002 Apr; 8(4):1251-7. PubMed ID: 11948140
[TBL] [Abstract][Full Text] [Related]
35. Synthesis of GnRH analogs having direct antitumor and low LH-releasing activity.
Mezô I; Seprôdi J; Vincze B; Pályi I; Kéri G; Vadász Z; Tóth G; Kovács M; Koppán M; Horváth JE; Kálnay A; Teplán I
Biomed Pept Proteins Nucleic Acids; 1996; 2(2):33-40. PubMed ID: 9346824
[TBL] [Abstract][Full Text] [Related]
36. GnRH agonist inhibits human telomerase reverse transcriptase mRNA expression in endometrial cancer cells.
Nagai N; Oshita T; Mukai K; Shiroyama Y; Shigemasa K; Ohama K
Int J Mol Med; 2002 Nov; 10(5):593-7. PubMed ID: 12373298
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
[TBL] [Abstract][Full Text] [Related]
38. Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor.
Maudsley S; Davidson L; Pawson AJ; Chan R; López de Maturana R; Millar RP
Cancer Res; 2004 Oct; 64(20):7533-44. PubMed ID: 15492280
[TBL] [Abstract][Full Text] [Related]
39. Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity.
Pályi I; Vincze B; Lovas S; Mezö I; Pató J; Kálnay A; Turi G; Gaál D; Mihalik R; Péter I; Teplán I; Murphy RF
Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2361-6. PubMed ID: 10051647
[TBL] [Abstract][Full Text] [Related]
40. Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas.
Clementi M; Sánchez C; Benitez DA; Contreras HR; Huidobro C; Cabezas J; Acevedo C; Castellón EA
Prostate; 2009 Jul; 69(10):1025-33. PubMed ID: 19301301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
